J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23
CHICAGO — When Leyla Shune first heard about a leaked abstract last month describing a dramatic 74% reduction in the risk of disease progression or death for Carvykti, J&J and Legend Biotech’s CAR-T therapy, she couldn’t contain her excitement.
“Amazement. Wonder. Standing ovation,” Shune, a physician at the University of Kansas Cancer Center, said of her reaction.
Monday morning at ASCO, the companies confirmed that figure, saying adults with multiple myeloma who had received between one and three previous treatments before Carvykti were 74% less likely to die or see their cancer progress compared to patients taking more standard regimens.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.